Finoriq research workspace
Kiniksa Pharmaceuticals International, plc (KNSA) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Kiniksa Pharmaceuticals International, plc (KNSA).
Company Snapshot
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Company
- Kiniksa Pharmaceuticals International, plc (KNSA)
- Ticker
- KNSA
- Market Cap
- $4.8B
- Latest Price
- $62.69
- Industry
- Biotech & Pharma
Kiniksa Pharmaceuticals International, plc (KNSA) Recent Insider Transactions
Recent market insider transaction records indexed for Kiniksa Pharmaceuticals International, plc (KNSA).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| Moat RossCHIEF OPERATING OFFICER | S | Disposed | -$79,513 | 2026-04-09 |
| Megna Michael RCHIEF ACCOUNTING OFFICER | S | Disposed | -$309,321 | 2026-04-09 |
| Moat RossCHIEF OPERATING OFFICER | S | Disposed | -$114,989 | 2026-04-06 |
| Patel Sanj KCHAIRMAN & CEO | S | Disposed | -$363,973 | 2026-04-06 |
| Quart Barry DClass A Ordinary Share | S | Disposed | -$345,050 | 2026-04-06 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.